Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 267 Results

December 9, 2019

Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 3, 2019

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

December 3, 2019

Relmada Therapeutics Announces Pricing of Public Offering of Common Stock

October 17, 2019

Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18

October 15, 2019

Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression

October 14, 2019

Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15

October 10, 2019

Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market

October 8, 2019

Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market

September 27, 2019

Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

July 29, 2019

Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression

«...13 141516 17 18...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top